Amidst the flurry of excitement in welcoming newborns, a cloud of concern looms over the safety of a recently introduced RSV vaccine, Beyfortus. French researchers, sounding the alarm bells, point to a distressing correlation between the vaccine rollout and an unprecedented surge in infant deaths. As the medical world grapples with these unsettling findings, questions about the vaccine’s thorough evaluation and its implications for newborns’ well-being continue to mount.
